Global research agenda for #antimicrobialresistance in human health by @WHO prioritizes 40 research topics for evidence generation to inform policy by 2030. https://t.co/YTyRbsveFe
cc #AntibioticGuardian
SHEA, IDSA and APIC have recently published updated recommendations on practical strategies to prevent healthcare-associated infections through hand hygiene.
Read the article here: https://t.co/TVlWXfc5eA
#InfectionControl#HygieneMatters#HandHygiene#InfectionPrevention
Wow!!
🔥A practice changing RCT🔥
26 US and Canada N: 887
Pip-tazo Vs Cefoxitin preop in OPEN Pancreatoduodenectomy (Whipple)
TZP as perioperative prophylaxis reduced postoperative SSI, pancreatic fistula,and multiple downstream sequelae of SSI
Cefoxitin🤔 https://t.co/eGDFZwZZbt
#ECCMID2023 EUCAST FAQs... ongoing problems with cefiderocol MIC testing has not been resolved - even the reference method has poor agreement between types of ID-CAMHB media: watch out for warning updates https://t.co/mM293XT7qP
Antimicrobial stewardship & infection prevention/control are connected. But how do GP nurses view their contribution to AMS? #GP nurses! Please consider taking part. Or, if working with practice nurses, let them know about the survey, closes soon! https://t.co/ti4ml7nq4C
Impact of #COVID19 on #AntibioticResistance is complex. Our systemic review found a trend to increasing Gram-negative AMR during the pandemic and a high degree of heterogeneity across studies. #ECCMID23#ECCMID2023
https://t.co/dKpvoazq8y
All about #Streptococcal#IE
After today's updates in #ECCMID2023 about the inclusion of various Streptococcus species in IE with few exceptions, I decided to compile a few important infographics on Streptococcal IE
1. Streptococcal grouping
2. Incidence of IE
#IDTwitter
🔥 Just published 🔥 @CMIJournal
The Dutch Working Party on Antibiotic Policy (SWAB) guideline for the approach to suspected antibiotic allergy
Presented today @ESCMID#ECCMID2023 by Prof Mark De Boer
🌟Cross reactivity in beta-lactam antibiotics🌟
EnJoY
https://t.co/80zCjr1gxZ
Select antibiotics with activity against carbapenem-resistant organisms. Green, susceptibility anticipated to be >80%; yellow, susceptibility anticipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be <30%.
#COVID19Guidelines update!
IDSA has released updated evidence summaries and clarified remarks on the use of #molnupiravir in the treatment of patients with COVID-19: https://t.co/InyRvQiYjp
We need to consider several different interventions to counter the threat of antimicrobial resistance (#AMR).
If we reduce the number of #antibiotics in the environment, improve infection prevention, and use diagnostics to help reduce unnecessary use, we can make a difference.